Galectin Therapeutics (PHPN) Ownership - Who Owns Galectin Therapeutics?
Galectin Therapeutics (PHPN) Ownership Overview
- 51.09% Insiders
- 3.88% Mutual Funds
- 0.28% Other Institutional Investors
- 4.29% ETFs
- 40.46% Public Companies and Individual Investors
The ownership structure of Galectin Therapeutics (DE:PHPN) stock is a mix of institutional, retail, and individual investors. Approximately 8.45% of the company’s stock is owned by Institutional Investors, 51.09% is owned by Insiders, and 40.46% is owned by Public Companies and Individual Investors.
The ownership structure of Galectin Therapeutics (DE:PHPN) stock is a mix of institutional, retail, and individual investors. Approximately 8.45% of the company’s stock is owned by Institutional Investors, 51.09% is owned by Insiders, and 40.46% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Feb 08, 2026 | Kary Eldred | $810 | |
| Jan 12, 2026 | Joel Lewis | $218,568 | |
| Dec 22, 2025 | Kevin D. Freeman | $19,470 | |
| Dec 22, 2025 | Kary Eldred | $2,611 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Richard E Uihlein | 44,741,553 | Insider | 44.36% | 141,875,465 |
| 10x Fund, L.p. | 5,614,457 | Insider | 5.57% | 17,803,443 |
| BlackRock, Inc. | 2,988,353 | Institution | 2.96% | 9,476,067 |
| Vanguard | 2,374,596 | Institution | 2.35% | 7,529,844 |
| Vanguard Index Funds | 2,116,148 | Institution | 2.10% | 6,710,305 |
| Ishares | 1,774,447 | Institution | 1.76% | 5,626,771 |
| Joel Lewis | 778,260 | Insider | 0.77% | 2,467,862 |
| Fidelity Salem Street Trust | 580,164 | Institution | 0.58% | 1,839,700 |
| Fidelity Concord Street Trust | 504,110 | Institution | 0.50% | 1,598,533 |
| Vanguard Scottsdale Funds | 328,636 | Institution | 0.33% | 1,042,105 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 2,116,148 | Institution | 2.10% | 6,710,305 |
| Fidelity Salem Street Trust | 580,164 | Institution | 0.58% | 1,839,700 |
| Fidelity Concord Street Trust | 504,110 | Institution | 0.50% | 1,598,533 |
| Vanguard Scottsdale Funds | 328,636 | Institution | 0.33% | 1,042,105 |
| Schwab Capital Trust | 116,397 | Institution | 0.12% | 369,095 |
| Goldman Sachs Trust | 77,051 | Institution | 0.08% | 244,329 |
| Tiaa-cref Funds | 63,710 | Institution | 0.06% | 202,024 |
| Vanguard Valley Forge Funds | 26,902 | Institution | 0.03% | 85,306 |
| Vanguard Institutional Index Funds | 24,567 | Institution | 0.02% | 77,902 |
| Valic Co I | 20,946 | Institution | 0.02% | 66,420 |
FAQ
Who Owns Galectin Therapeutics (DE:PHPN)?
According to the latest TipRanks data, approximately 8.45% of the company's stock is held by institutional investors, 51.09% is held by insiders, and 40.46% is held by public companies and individual investors.
What percentage of Galectin Therapeutics (DE:PHPN) stock is held by institutional investors?
According to the latest TipRanks data, approximately 8.45% of Galectin Therapeutics (DE:PHPN) stock is held by institutional investors: 3.88% by mutual funds, 4.29% by ETFs and 0.28% by other institutional investors.
What percentage of Galectin Therapeutics (DE:PHPN) stock is held by retail investors?
According to the latest TipRanks data, approximately 40.46% of Galectin Therapeutics (DE:PHPN) stock is held by public companies and individual investors.
Who owns the most shares of Galectin Therapeutics (DE:PHPN)?
Richard E Uihlein owns the most shares of Galectin Therapeutics (DE:PHPN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
